全文获取类型
收费全文 | 593篇 |
免费 | 35篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 30篇 |
妇产科学 | 17篇 |
基础医学 | 80篇 |
口腔科学 | 5篇 |
临床医学 | 34篇 |
内科学 | 193篇 |
皮肤病学 | 21篇 |
神经病学 | 39篇 |
特种医学 | 11篇 |
外科学 | 80篇 |
预防医学 | 42篇 |
眼科学 | 10篇 |
药学 | 26篇 |
中国医学 | 1篇 |
肿瘤学 | 45篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 15篇 |
2021年 | 18篇 |
2020年 | 25篇 |
2019年 | 23篇 |
2018年 | 13篇 |
2017年 | 21篇 |
2016年 | 25篇 |
2015年 | 24篇 |
2014年 | 30篇 |
2013年 | 29篇 |
2012年 | 48篇 |
2011年 | 55篇 |
2010年 | 35篇 |
2009年 | 16篇 |
2008年 | 37篇 |
2007年 | 47篇 |
2006年 | 44篇 |
2005年 | 48篇 |
2004年 | 22篇 |
2003年 | 20篇 |
2002年 | 20篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
排序方式: 共有637条查询结果,搜索用时 15 毫秒
631.
Benjamin Heidrich Beatriz C. Serrano Ramazan Idilman Gökhan Kabaçam Birgit Bremer Regina Raupach Fatih O. Önder Katja Deterding Behrend J. Zacher Andrzej Taranta Hakan Bozkaya Kalliopi Zachou Hans L. Tillmann Abdurrahman M. Bozdayi Michael P. Manns Cihan Yurdaydın Heiner Wedemeyer 《Liver international》2012,32(9):1415-1425
632.
Extrapulmonary neuroendocrine carcinoma is uncommon. Cases of primary neuroendocrine carcinoma of the breast have been reported, though rare. We report the case of a 53-year-old woman who underwent a mastectomy for breast carcinoma and presented three years later with synchronous masses in the head of the pancreas and liver. Fine-needle aspiration of both organs revealed a neuroendocrine carcinoma. The original breast tumor was reviewed and found to express neuroendocrine markers. A diagnosis of a primary neuroendocrine carcinoma of the breast was rendered. 相似文献
633.
Konstantinos A. Toulis PhD John P. Bilezikian PhD G. Neil Thomas PhD Wasim Hanif PhD Kalliopi Kotsa PhD Rasiah Thayakaran PhD Deepiksana Keerthy Abd A Tahrani PhD Krishnarajah Nirantharakumar MD 《Diabetes, obesity & metabolism》2018,20(4):1070-1074
An increase in fracture risk has been reported in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, possibly mediated by effects induced by all members of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor class. It is unclear whether initiation of dapagliflozin is followed by an increase in the risk of fracture; therefore, we performed a population‐based, open cohort study (from January 2013 to January 2016) using The Health Improvement Network (THIN). A total of 22 618 people with T2DM (4548 exposed to dapagliflozin and 18 070 receiving standard antidiabetic treatment, matched for age, sex, body mass index and diabetes duration) with no history of fractures at baseline were included. The primary outcome was the occurrence of any fragility fracture (hip, spine, wrist) during the observation period. Risk of any fracture served as a secondary outcome. Adjusted hazard rate ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression. A total of 289 fractures (132 fragility fractures) were recorded. No difference in the risk of fragility fracture was detected between participants prescribed dapagliflozin and matched control participants (crude HR 0.90, 95% CI 0.59‐1.39, P = .645; adjusted HR 0.87, 95% CI 0.56‐1.35, P = .531). Similarly, no difference in the risk of any fracture was detected (adjusted HR 0.89, 95% CI 0.66‐1.20; P = .427). Sensitivity analyses limited to the subset of the population at high risk of fracture produced similar results; thus, there was no evidence to suggest an increase in the risk of treatment‐emergent fractures in patients with T2DM who initiated treatment with dapagliflozin. 相似文献
634.
Brenda Moura Alberto Aimo Abdallah Al-Mohammad Kalliopi Keramida Tuvia Ben Gal Sharmila Dorbala Giancarlo Todiere Matteo Cameli Andrea Barison Antoni Bayes-Genis Ralph Stephan von Bardeleben Chiara Bucciarelli-Ducci Victoria Delgado Ify R. Mordi Petar Seferovic Gianluigi Savarese Jelena Čelutkienė Claudio Rapezzi Michele Emdin Andrew Coats Marco Metra Giuseppe Rosano 《European journal of heart failure》2023,25(9):1493-1506
Left ventricular (LV) hypertrophy consists in an increased LV wall thickness. LV hypertrophy can be either secondary, in response to pressure or volume overload, or primary, i.e. not explained solely by abnormal loading conditions. Primary LV hypertrophy may be due to gene mutations or to the deposition or storage of abnormal substances in the extracellular spaces or within the cardiomyocytes (more appropriately defined as pseudohypertrophy). LV hypertrophy is often a precursor to subsequent development of heart failure. Cardiovascular imaging plays a key role in the assessment of LV hypertrophy. Echocardiography, the first-line imaging technique, allows a comprehensive assessment of LV systolic and diastolic function. Cardiovascular magnetic resonance provides added value as it measures accurately LV and right ventricular volumes and mass and characterizes myocardial tissue properties, which may provide important clues to the final diagnosis. Additionally, scintigraphy with bone tracers is included in the diagnostic algorithm of cardiac amyloidosis. Once the diagnosis is established, imaging findings may help predict future disease evolution and inform therapy and follow-up. This consensus document by the Heart Failure Association of the European Society of Cardiology provides an overview of the role of different cardiac imaging techniques for the differential diagnosis and management of patients with LV hypertrophy. 相似文献
635.
Kalliopi Michoglou Amsajini Ravinthiranathan Saw San Ti Saoirse Dolly Kiruthikah Thillai 《World Journal of Clinical Cases》2023,11(12):2631-2636
Pancreatic cancer is a highly devastating disease with high mortality rates. Even patients who undergo potential curative surgery have a high risk for recurrence. The incidence of depression and anxiety are higher in patients with cancer than the general population. However, patients with pancreatic cancer are at most of risk of both depression and anxiety and there seems to be a biological link. In some patients, depression seems to be a precursor to pancreatic cancer. In this article we discuss the biological link between depression anxiety and hepatobiliary malignancies and discuss treatment strategies. 相似文献
636.
George Papatheodoridis Konstantinos Mimidis Spilios Manolakopoulos Christos Triantos Ioannis Vlachogiannakos Christos Veretanos Melanie Deutsch Stylianos Karatapanis Ioannis Goulis Ioannis Elefsiniotis Evangelos Cholongitas Vassilios Sevastianos Dimitrios Christodoulou Dimitrios Samonakis Emanuel Manesis Andreas Kapatais Nikolaos Papadopoulos Panagiota Ioannidou Georgios Germanidis George Giannoulis Dimitra Lakiotaki Dionysios Kogias Ηarikleia Kranidioti Konstantinos Zisimopoulos Maria Mela George Kontos Paraskevi Fytili Chrysanthi Manolaka Polyxeni Agorastou Spyridon I. Pantzios Margarita Papatheodoridi Dimitrios Karagiannakis Eleni Geladari Nikolaos Psychos Kalliopi Zachou Anna Chalkidou Anastasia Spanoudaki Konstantinos Thomopoulos George Dalekos 《Liver international》2023,43(9):1879-1889
Background and Aims
Hepatitis D virus (HDV) underdiagnosis remains common. We assessed the HDV screening and prevalence rates in HBsAg-positive patients seen at tertiary liver centres throughout Greece as well as factors affecting HDV diagnosis.Methods
All adult HBsAg-positive patients seen within the last 5 years were included. Non-screened patients who visited or could be recalled to the clinics over a 6-month period were prospectively tested for anti-HDV.Results
Of 5079 HBsAg-positive patients, 53% had anti-HDV screening (41% before and 12% after study initiation). Pre-study (8%–88%) and total screening rates (14%–100%) varied widely among centres. Screening rates were associated with older age, known risk group, elevated ALT, centre location and size and period of first visit. Anti-HDV prevalence was 5.8% without significant difference in patients screened before (6.1%) or after study initiation (4.7%, p = 0.240). Anti-HDV positivity was associated with younger age, parenteral drug use, born abroad, advanced liver disease and centre location. Overall, HDV RNA detectability rate was 71.6% being more frequent in anti-HDV-positive patients with elevated ALT, advanced liver disease and hepatitis B therapy.Conclusions
Anti-HDV screening rates and recall capabilities vary widely among Greek liver clinics being higher in HBsAg-positive patients of known risk group with active/advanced liver disease seen at smaller centres, while non-medical factors are also important. Anti-HDV prevalence varies throughout Greece being higher in patients born abroad with younger age, parenteral drug use and advanced liver disease. Viremia is more frequently but not exclusively detected in anti-HDV-positive patients with elevated ALT and advanced liver disease. 相似文献637.